| Schedule of common stock issued roll forward |
The following table represents a share reconciliation of the Company’s common stock issued for the periods presented: | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Common stock: | | | | | | | | | Balance, beginning of period | | 213,853,720 | | 201,449,583 | | 207,785,762 | | 195,028,207 | Shares issued for stock options exercised | | 41,322 | | 10,264 | | 50,032 | | 82,546 | Agent growth incentive stock-based compensation | | 581,994 | | 662,874 | | 2,216,643 | | 1,968,559 | Agent equity stock-based compensation | | 5,630,961 | | 2,520,959 | | 12,718,059 | | 7,564,368 | Other stock-based compensation | | 35,086 | | - | | 87,936 | | - | Other share activity | | - | | - | | (2,715,349) | | - | Balance, end of period | | 220,143,083 | | 204,643,680 | | 220,143,083 | | 204,643,680 |
|
| Changes in the Company's stock compensation liability |
The following table illustrates changes in the Company’s stock-based compensation liability for the periods presented: | | | | | Amount | Balance, December 31, 2024 | | $ 5,045 | Stock grant liability increase year to date | | 2,736 | Stock grants reclassified from liability to equity year to date | | (1,999) | Balance, December 31, 2025 | | $ 5,782 | Stock grant liability increase year to date | | 2,354 | Stock grants reclassified from liability to equity year to date | | (1,315) | Balance, September 30, 2026 | | $ 6,821 |
|